China NMPA Discloses No. 057 Reference Listed Drug (RLD) List for Public Industry Comments
China’s NMPA announced on March 25, 2022, the issue of the 57th batch of RLD (Reference Listed Drug) for public industry comments.
- About GRP
- Countries
- Canada’s Health Canada
- United States’ FDA
- Brazil
- Mexico’s COFEPRIS
- Europe’s EMA
- Australia
- China
- Japan’s PMDA
- Korea’s Ministry of Food and Drug Safety (MFDS)
- Taiwan’s Food and Drug Administration (TFDA)
- Singapore’s HSA
- India’s CDSCO
- Services
- Resource Center
- RI Platform
- Japan Regulatory Intelligence (RI)
- China (NMPA) Regulatory Intelligence
- Brazil
- Mexico Regulatory Intelligence (RI)
- USA Regulatory Intelligence (RI)
- Contact Us
Menu